Henlius claims win for PD-1 drug in small cell lung cancer
Immuno-oncology latecomer GSK shows off PD-1 drug data
BMS and Nektar’s combination latest in frenzied immunotherapy field
BMS and Nektar to pair Opdivo with natural killer cell drug
As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.
Promise for combination approach to cancer